Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular Inc. (LMAT) Form 4: Dorian Paul LeBlanc, identified as Chief Financial Officer and a director, reported a transaction dated 09/04/2025. The filing records the acquisition of dividend equivalent rights that accrued on a restricted stock unit award originally granted on 03/10/2025. Each dividend equivalent right is the economic equivalent of one share of the company’s common stock. The report shows an acquisition at $0 and a post-transaction beneficial ownership figure of 8.4578 (direct). The form is signed on the filing by Nathan Ulrich on 09/08/2025.
LeMaitre Vascular, Inc. (LMAT) reporting person Joseph P. Pellegrino Jr., a company director, reported accruals of dividend equivalent rights on 09/04/2025 tied to previously granted restricted stock unit (RSU) and performance share unit (PSU) awards. The filing itemizes seven separate dividend-equivalent accruals that vest proportionately with their underlying awards, referencing grant dates from 12/2/2020 through 12/6/2024. The report shows the reporting person acquired 19.0048 dividend equivalent rights on 09/04/2025, which correspond to 176.2176 shares of common stock economic equivalent following the transactions. The entries are non-cash accruals (price listed as $0) and were certified by signature on 09/08/2025.
David B. Roberts, serving as President and Director of LeMaitre Vascular, acquired a series of dividend equivalent rights tied to previously granted restricted stock units and performance share units. The rights, recorded on 09/04/2025, represent the economic equivalent of shares of the issuer's common stock and arise from awards dated 12/2/2020, 12/11/2021, 12/12/2022, 12/8/2023, 12/6/2024 and 2/18/2025. The reported increments of dividend equivalent rights total 18.5799 share-equivalents across eight award lines, each showing zero purchase price and classified as direct ownership. The table lists the post-transaction beneficially owned share-equivalents for each line, indicating modest accruals that vest proportionately with the underlying awards.
LeMaitre Vascular, Inc. (LMAT) insider report: George W. LeMaitre, Chairman and CEO, reported transactions on 09/03/2025 showing two non-derivative dispositions of 10,600 shares each (transaction code G), reducing his reported beneficial ownership from 1,716,403 to 1,705,803 shares following the second line item. The filing also records multiple dividend equivalent rights credited on restricted stock and performance share unit awards that convert economically to common shares; individual accruals range from 2.0944 to 10.238 and represent fractional share equivalents under vesting schedules. The form is signed and dated 09/05/2025.
LeMaitre Vascular insider sale disclosed on Form 4. Director Lawrence J. Jasinski sold 976 shares of Common Stock on 08/12/2025 at $92.78 per share, and after the transaction beneficially owned 4,773 shares directly. The filing lists the issuer as LeMaitre Vascular, Inc. (LMAT) and indicates the Form 4 was filed as an individual report. The document contains no options or other derivative transactions.
LeMaitre Vascular President and Director David B. Roberts reported option exercises and subsequent open-market sales on 08/11/2025. The Form 4 shows Mr. Roberts acquiring shares upon exercise of previously granted stock options and selling multiple blocks of common stock the same day.
The filing lists option exercises generating 3,979, 123 and 6,713 shares at exercise prices of $37.29 and $35.48. On 08/11/2025 he sold blocks of 3,718, 384 and 6,713 shares at weighted average prices of $92.5337, $91.5484 and $92.3549, respectively. The filing shows beneficial ownership of 17,976 shares following these transactions. The Form is signed by Nathan Ulrich on 08/13/2025 as submitted.
Bridget A. Ross, a director of LeMaitre Vascular (LMAT), reported exercising 2,500 vested stock options on 08/08/2025 with an exercise price of $37.29, and concurrently selling 2,500 common shares at $94.00 per share. The option exercised was fully vested and had an expiration date of 12/02/2025. The sequence increased her direct holdings to 5,416 shares then, after the sale, left her with 2,916 shares of common stock beneficially owned.
John A. Roush, a director of LeMaitre Vascular (LMAT), exercised stock options to acquire 7,500 common shares at an exercise price of $37.29 on 08/08/2025 and 08/11/2025, as reported in Table II. The form states these option exercises converted derivative holdings into common stock.
Roush also sold a total of 7,500 shares across transactions on 08/08/2025 and 08/11/2025 at reported weighted-average prices of $93.4872, $92.783 and $91.8181, with execution ranges between $91.38 and $94.00. Following these transactions, the reporting person beneficially owned 2,916 shares of LeMaitre Vascular.
LeMaitre Vascular, Inc. (LMAT) filed a Form 144 proposing the sale of 976 common shares through Morgan Stanley Smith Barney LLC on 08/12/2025 on NASDAQ, with an aggregate market value of $90,553.28. The notice indicates 22,637,522 shares outstanding, so the position is a very small fraction of the company.
The 976 shares were acquired from the issuer as a mix of restricted stock and performance shares across five lots on dates in December 2024 and March 8, 2025 (198, 205, 201, 171, and 201 shares, which total 976). The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information about the issuer.
LeMaitre Vascular (LMAT) filed a Form 144 reporting a proposed sale of 6,561 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $607,229.74. The filing lists 22,637,522 shares outstanding and an approximate sale date of 08/11/2025. The securities were acquired by a stock option exercise on 08/11/2025 with payment in cash.
The filing also discloses a recent sale by JOHN ADAM ROUSH of 939 shares on 08/08/2025 for $87,784.39. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.